CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a significant growth in short interest in May. As of May 29th, there was short interest totaling 48,551 shares, a growth of 58.7% from the May 14th total of 30,584 shares. Based on an average daily volume of 128,880 shares, the short-interest ratio is currently 0.4 days. Currently, 3.3% of the company’s shares are sold short.

Insider Buying and Selling

In other news, Director Faith L. Charles bought 7,100 shares of the stock in a transaction on Monday, May 18th. The stock was purchased at an average price of $4.79 per share, with a total value of $34,009.00. Following the completion of the purchase, the director owned 7,100 shares of the company’s stock, valued at approximately $34,009. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.01% of the company’s stock.

Institutional Investors Weigh In On CNS Pharmaceuticals

Several hedge funds have recently bought and sold shares of CNSP. Boothbay Fund Management LLC bought a new stake in CNS Pharmaceuticals in the 4th quarter valued at $71,000. Ikarian Capital LLC bought a new stake in CNS Pharmaceuticals in the 4th quarter valued at $241,000. Finally, Armistice Capital LLC bought a new stake in CNS Pharmaceuticals in the 2nd quarter valued at $335,000. 14.02% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, CNS Pharmaceuticals has a consensus rating of “Hold” and an average price target of $20.00.

CNS Pharmaceuticals Price Performance

Shares of CNS Pharmaceuticals stock opened at $4.53 on Thursday. The firm has a market cap of $6.61 million, a price-to-earnings ratio of -0.15 and a beta of 3.06. The stock’s 50-day moving average is $4.29 and its 200-day moving average is $4.59. CNS Pharmaceuticals has a one year low of $1.90 and a one year high of $12.36.

CNS Pharmaceuticals (NASDAQ:CNSP) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($7.30) EPS for the quarter, beating analysts’ consensus estimates of ($8.82) by $1.52.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.